News Express

Science News: Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis

March 29, 2021

This was a retrospective cohort study conducted in a university hospital in Sweden to compare efficacy between rituximab and conventional immunosuppressants in the refractory and newly diagnosed generalized myasthenia gravis.

Science News: Which Ultrasound Parameter is More Accurate in the Diagnosis of Carpal Tunnel Syndrome

March 17, 2021

Ultrasound (US) can be useful to diagnosing carpal tunnel syndrome (CTS). Most US CTS studies have looked at median nerve cross sectional area (CSA). Others use resistive index (RI) or strain ratio (SR) as the criteria. This study compared CSA with RI and SR in CTS.

Science News: Serum Neurofilament Light Chain Predicts Long-Term Prognosis in Guillain-Barré Syndrome Patients

February 16, 2021

The neurofilament light (NfL) chain is an increasingly studied biomarker for axonal injury, previously studied in Guillain-Barré syndrome (GBS). This study evaluates it as a prognostic maker in GBS.

Science News: Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series

February 02, 2021

Eculizumab has been approved and used for AChR antibody positive myasthenia gravis but little is known about its efficacy for AChR seronegative cases. In this small retrospective study (N=6), treatment outcome with eculizumab for AChR negative patients was assessed.

Science News: Placebo Effect in Chronic Inflammatory Demyelinating Polyneuropathy: The PATH Study and a Systematic Review

January 19, 2021

Placebos (pharmacologically inert preparations) are used in treatment trials to assess the true effect of trial medication. Placebo responses have been noted in chronic inflammatory demyelinating polyneuropathy (CIDP) trials including the most recent PATH trial investigating subcutaneous IVIG as maintenance therapy.